Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP C Frank Bennett sold 12,250 shares of the company’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total transaction of $796,250.00. Following the sale, the senior vice president now owns 27,291 shares of the company’s stock, valued at approximately $1,773,915. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

C Frank Bennett also recently made the following trade(s):

  • On Monday, July 24th, C Frank Bennett sold 10,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $59.29, for a total transaction of $592,900.00.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded up 1.15% during midday trading on Friday, reaching $64.39. 1,631,810 shares of the company’s stock traded hands. The stock has a 50 day moving average of $56.15 and a 200-day moving average of $50.31. Ionis Pharmaceuticals, Inc. has a 12 month low of $24.58 and a 12 month high of $65.51. The stock has a market cap of $8.01 billion, a P/E ratio of 309.57 and a beta of 3.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm’s quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) earnings per share. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.16) EPS for the current fiscal year.

WARNING: “Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $796,250.00 in Stock” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/20/ionis-pharmaceuticals-inc-ions-svp-sells-796250-00-in-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Intl Fcstone Inc. acquired a new position in shares of Ionis Pharmaceuticals during the second quarter valued at about $598,000. WFG Advisors LP boosted its holdings in Ionis Pharmaceuticals by 77.2% during the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after purchasing an additional 1,655 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Ionis Pharmaceuticals during the second quarter worth about $381,000. Verition Fund Management LLC purchased a new position in Ionis Pharmaceuticals during the second quarter worth about $742,000. Finally, Bank of Nova Scotia purchased a new position in Ionis Pharmaceuticals during the second quarter worth about $1,526,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Several brokerages have commented on IONS. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 target price for the company in a research report on Tuesday. Stifel Nicolaus reiterated a “hold” rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $30.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $69.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Ionis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $50.04.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.